

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptasel1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 01	New pricing for the Save Answers for SciFinder Wizard within STN Express with Discover!
NEWS	4	OCT 28	KOREAPAT now available on STN
NEWS	5	NOV 30	PHAR reloaded with additional data
NEWS	6	DEC 01	LISA now available on STN
NEWS	7	DEC 09	12 databases to be removed from STN on December 31, 2004
NEWS	8	DEC 15	MEDLINE update schedule for December 2004
NEWS	9	DEC 17	ELCOM reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	10	DEC 17	COMPUAB reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	11	DEC 17	SOLIDSTATE reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	12	DEC 17	CERAB reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	13	DEC 17	THREE NEW FIELDS ADDED TO IFIPAT/IFIUDB/IFICDB
NEWS	14	DEC 30	EPFULL: New patent full text database to be available on STN
NEWS	15	DEC 30	CAPLUS - PATENT COVERAGE EXPANDED
NEWS	16	JAN 03	No connect-hour charges in EPFULL during January and February 2005
NEWS	17	JAN 11	CA/CAPLUS - Expanded patent coverage to include Russia (Federal Institute of Industrial Property)
NEWS EXPRESS			JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:46:41 ON 19 JAN 2005

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 10:46:52 ON 19 JAN 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 17 JAN 2005 HIGHEST RN 815574-28-8

DICTIONARY FILE UPDATES: 17 JAN 2005 HIGHEST RN 815574-28-8

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004


Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10822259.str



chain nodes :

15

ring nodes :

2 3 4 5 6 7 10 11 12 13 14

ring/chain nodes :

1 8 9

ring/chain bonds :

1-2 1-8 1-9 4-12 14-15

ring bonds :

2-3 2-7 3-4 4-5 5-6 6-7 10-11 10-14 11-12 12-13 13-14

exact/norm bonds :

1-2 4-12 10-11 10-14 11-12 12-13 13-14 14-15

normalized bonds :

1-8 1-9 2-3 2-7 3-4 4-5 5-6 6-7


Match level :

1:CLASS 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:CLASS 9:CLASS 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom

L1

STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 11
GENERIC GROUP NOT VALID HERE
Generic groups may not be used in these circumstances:

1. Any generic group node (e.g., Hy) in a ring.
2. An Ak node attached to another Ak node.

=> log y
COST IN U.S. DOLLARS
FULL ESTIMATED COST

	SINCE FILE ENTRY	TOTAL SESSION
	1.29	1.50

STN INTERNATIONAL LOGOFF AT 10:48:37 ON 19 JAN 2005

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptasel1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 01	New pricing for the Save Answers for SciFinder Wizard within STN Express with Discover!
NEWS	4	OCT 28	KOREAPAT now available on STN
NEWS	5	NOV 30	PHAR reloaded with additional data
NEWS	6	DEC 01	LISA now available on STN
NEWS	7	DEC 09	12 databases to be removed from STN on December 31, 2004
NEWS	8	DEC 15	MEDLINE update schedule for December 2004
NEWS	9	DEC 17	ELCOM reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	10	DEC 17	COMPUAB reloaded; updating to resume; current-awareness

alerts (SDIs) affected
 NEWS 11 DEC 17 SOLIDSTATE reloaded; updating to resume; current-awareness
 alerts (SDIs) affected
 NEWS 12 DEC 17 CERAB reloaded; updating to resume; current-awareness
 alerts (SDIs) affected
 NEWS 13 DEC 17 THREE NEW FIELDS ADDED TO IFIPAT/IFIUDB/IFICDB
 NEWS 14 DEC 30 EPFULL: New patent full text database to be available on STN
 NEWS 15 DEC 30 CAPLUS - PATENT COVERAGE EXPANDED
 NEWS 16 JAN 03 No connect-hour charges in EPFULL during January and
 February 2005
 NEWS 17 JAN 11 CA/CAPLUS - Expanded patent coverage to include Russia
 (Federal Institute of Industrial Property)

 NEWS EXPRESS JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT
 MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
 AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005

 NEWS HOURS STN Operating Hours Plus Help Desk Availability
 NEWS INTER General Internet Information
 NEWS LOGIN Welcome Banner and News Items
 NEWS PHONE Direct Dial and Telecommunication Network Access to STN
 NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:52:03 ON 19 JAN 2005

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 10:52:16 ON 19 JAN 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 17 JAN 2005 HIGHEST RN 815574-28-8

DICTIONARY FILE UPDATES: 17 JAN 2005 HIGHEST RN 815574-28-8

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.


Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:

<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10822259b.str



chain nodes :

15

ring nodes :

2 3 4 5 6 7 10 11 12 13 14

ring/chain nodes :

1 8 9

chain bonds :

14-15

ring/chain bonds :

1-2 1-8 1-9 4-12

ring bonds :

2-3 2-7 3-4 4-5 5-6 6-7 10-11 10-14 11-12 12-13 13-14

exact/norm bonds :

1-2 4-12 10-11 10-14 11-12 12-13 13-14 14-15

normalized bonds :

1-8 1-9 2-3 2-7 3-4 4-5 5-6 6-7

Match level :

1:CLASS 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:CLASS 9:CLASS 10:Atom


11:Atom 12:Atom 13:Atom 14:Atom 15:Atom

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 11

SAMPLE SEARCH INITIATED 10:52:33 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 3476 TO ITERATE

28.8% PROCESSED 1000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

2 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 65985 TO 73055
PROJECTED ANSWERS: 2 TO 297

L2 2 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 10:52:38 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 68703 TO ITERATE

100.0% PROCESSED 68703 ITERATIONS
SEARCH TIME: 00.00.07

78 ANSWERS

L3 78 SEA SSS FUL L1

=> file caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	161.33	161.54

FILE 'CAPLUS' ENTERED AT 10:52:49 ON 19 JAN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Jan 2005 VOL 142 ISS 4
FILE LAST UPDATED: 18 Jan 2005 (20050118/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3

L4 4 L3


=> d ibib abs hitstr tot

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:857186 CAPLUS
DOCUMENT NUMBER: 141:350173
TITLE: Preparation of 3-([1,2,4]oxadiazol-3-yl)benzoic acid compounds and their use for nonsense suppression and the treatment of genetic disease
INVENTOR(S): Karp, Gary Mitchell; Hwang, Seongwoo; Chen, Guangming;
PATENT ASSIGNEE(S): Almadest, Neil Gregory
SOURCE: U.S. Pat. Appl. Publ., 67 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004204461	A1	20041014	US 2004-822259	20040409
WO 2004091502	A2	20041028	WO 2004-US11106	20040409
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CI, CO, CR, CU, CZ, DE, DK, DM, DO, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2003-461988 P 20030411


OTHER SOURCE(S): MARPAT 141:350173
GI




AB The title compds. [I; Z = (un)substituted aryl, heteroaryl, cycloalkyl, etc.; R1 = H, (un)substituted alkyl, cycloalkyl, etc.; R2-R5 = H, (un)substituted alkyl, alkenyl, aryl, etc.; with the proviso], useful for treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay, or ameliorating one or more symptoms associated therewith, were prepared and formulated.

E.g., a multi-step synthesis of I [Z = 2-FC6H4; R1-R5 = H], starting from 3-cyanobenzoic acid, was given. The compds. I were tested for potency and/or efficacy of protein synthesis in the cell-based luciferase assay. Their activity was classified in order from extremely high to significant


L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
INDEX NAME)




RN 775303-88-3 CAPLUS
CN Benzoic acid, 3-[5-(1-naphthalenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)



RN 775303-89-4 CAPLUS
CN Benzoic acid, 3-[5-(4-methylphenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)



RN 775303-90-7 CAPLUS
CN Benzoic acid, 3-[5-(1,1'-biphenyl)-4-yl]-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 775303-91-8 CAPLUS
CN Benzoic acid, 3-[5-[4-(2-methylpropyl)phenyl]-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(Table 1). Also, methods of using and pharmaceutical compns. comprising the title compds. I are disclosed.


IT 199447-11-5P 775303-86-1P 775303-87-2P
775303-88-3P 775303-89-4P 775303-90-7P
775303-91-8P 775303-92-9P 775303-93-0P
775303-94-1P 775303-95-2P 775303-96-3P
775303-97-4P 775303-98-5P 775304-00-2P
775304-01-3P 775304-02-4P 775304-03-5P
775304-04-6P 775304-05-7P 775304-07-9P
775304-08-0P 775304-09-1P 775304-11-5P
775304-12-6P 775304-14-0P 775304-18-2P
775304-19-3P 775304-20-6P 775304-21-7P
775304-22-8P 775304-23-9P 775304-24-2P
775304-28-4P 775304-29-5P 775304-31-9P
775304-32-0P 775304-34-2P 775304-35-3P
775304-36-4P 775304-37-5P 775304-39-7P
775304-40-0P 775304-41-1P 775304-42-2P
775304-44-4P 775304-45-5P 775304-46-6P
775304-47-7P 775304-48-0P 775304-49-9P
775304-50-2P 775304-51-3P 775304-52-4P
775304-53-5P 775304-54-6P 775304-55-7P
775304-56-8P 775304-57-9P 775304-58-0P
775304-59-1P 775304-61-5P 775304-62-6P
775304-63-7P 775304-65-9P 775304-66-0P
775304-67-1P 775304-68-2P 775304-75-1P
775304-76-2P 775304-77-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3-([1,2,4]oxadiazol-3-yl)benzoic acid compds. and their use for nonsense suppression and the treatment of genetic disease)

RN 199447-11-5 CAPLUS
CN Benzoic acid, 3-[5-(4-cyanophenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 775303-86-1 CAPLUS
CN Benzoic acid, 3-[5-(3-chlorophenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 775303-87-2 CAPLUS
CN Benzoic acid, 3-[5-(4-(pentyloxy)phenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 775303-92-9 CAPLUS
CN Benzoic acid, 3-[5-(phenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 775303-93-0 CAPLUS
CN Benzoic acid, 3-[5-(cyclohexyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 775303-94-1 CAPLUS
CN Benzoic acid, 3-[5-(3,4,5-trimethoxyphenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 775303-95-2 CAPLUS
CN Benzoic acid, 3-[5-(4-nitrophenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 775303-96-3 CAPLUS
CN Benzoic acid, 3-[5-(4-methoxyphenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 775303-97-4 CAPLUS
CN Benzoic acid, 3-[5-(2-methylphenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 775303-98-5 CAPLUS
CN Benzoic acid, 3-[5-(1,3-benzodioxol-5-yl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 775304-00-2 CAPLUS
CN Benzoic acid, 3-[5-bis(3,5-bis(trifluoromethyl)phenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 775304-05-7 CAPLUS
CN Benzoic acid, 3-[5-(2-furanyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 775304-07-9 CAPLUS
CN Benzoic acid, 3-[5-(2,1,3-benzoxadiazol-5-yl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 775304-08-0 CAPLUS
CN Benzoic acid, 3-[5-(4-(chloromethyl)phenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 775304-09-1 CAPLUS
CN Benzoic acid, 3-[5-(4-(1,1-dimethylethyl)phenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 775304-11-5 CAPLUS
CN Benzoic acid, 3-[5-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 775304-01-3 CAPLUS
CN Benzoic acid, 3-[5-(4-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 775304-02-4 CAPLUS
CN Benzoic acid, 3-[5-(4-(dimethylamino)phenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 775304-03-5 CAPLUS
CN Benzoic acid, 3-[5-(3-methoxyphenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 775304-04-6 CAPLUS
CN Benzoic acid, 3-[5-(3-methoxyphenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 775304-12-6 CAPLUS
CN Benzoic acid, 3-[5-(2-thienyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 775304-14-8 CAPLUS
CN Benzoic acid, 3-[5-(3-cyclopentyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 775304-18-2 CAPLUS
CN Benzoic acid, 3-[5-(2-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 775304-19-3 CAPLUS
CN Benzoic acid, 3-[5-(2,6-difluorophenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RN 775304-20-6 CAPLUS
 CN Benzoic acid, 3-[5-(4-ethylphenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 775304-21-7 CAPLUS
 CN Benzoic acid, 3-[5-(3,4-difluorophenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)



RN 775304-22-8 CAPLUS
 CN Benzoic acid, 3-[5-(3-methylphenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 775304-23-9 CAPLUS
 CN Benzoic acid, 3-[5-(4-(1H-pyrrol-1-yl)phenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 775304-26-2 CAPLUS
 CN Benzoic acid, 3-[5-(2,5-difluorophenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 775304-34-2 CAPLUS
 CN Benzoic acid, 3-[5-(5-isoxazolyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)



RN 775304-35-3 CAPLUS
 CN Benzoic acid, 3-[5-(6-chloro-3-pyridinyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 775304-36-4 CAPLUS
 CN Benzoic acid, 3-[5-[3-(2-chlorophenyl)-5-methyl-4-isoxazolyl]-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 775304-37-5 CAPLUS
 CN Benzoic acid, 3-[5-[3-(2-chloro-6-fluorophenyl)-5-methyl-4-isoxazolyl]-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 775304-28-4 CAPLUS
 CN Benzoic acid, 3-[5-(2-chlorophenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)



RN 775304-29-5 CAPLUS
 CN Benzoic acid, 3-[5-[3-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 775304-31-9 CAPLUS
 CN Benzoic acid, 3-[5-(2,5-dimethyl-3-furanyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 775304-32-0 CAPLUS
 CN Benzoic acid, 3-[5-(3-methyl-2-thienyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 775304-39-7 CAPLUS
 CN Benzoic acid, 3-[5-(2,4-difluorophenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 775304-40-0 CAPLUS
 CN Benzoic acid, 3-[5-(3-pyridinyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 775304-41-1 CAPLUS
 CN Benzoic acid, 3-[5-(4-pyridinyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 775304-42-2 CAPLUS
 CN Benzoic acid, 3-(5-cyclobutyl-1,2,4-oxadiazol-3-yl)- (9CI) (CA INDEX NAME)




RN 775304-44-4 CAPLUS
CN Benzoic acid, 3-[5-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-3-yl]- (9CI)
(CA INDEX NAME)




RN 775304-45-5 CAPLUS
CN Benzoic acid, 3-[5-(2-chloro-3-pyridinyl)-1,2,4-oxadiazol-3-yl]- (9CI)
(CA INDEX NAME)




RN 775304-46-6 CAPLUS
CN Benzoic acid, 3-[5-(1-acetyl-4-piperidinyl)-1,2,4-oxadiazol-3-yl]- (9CI)
(CA INDEX NAME)




RN 775304-47-7 CAPLUS
CN Benzoic acid, 3-[5-benzo[b]thien-2-yl-1,2,4-oxadiazol-3-yl]- (9CI)
(CA INDEX NAME)




RN 775304-52-4 CAPLUS
CN Benzoic acid, 3-[5-(2,2-difluoro-1,3-benzodioxol-5-yl)-1,2,4-oxadiazol-3-yl]- (9CI)
(CA INDEX NAME)




RN 775304-53-5 CAPLUS
CN Benzoic acid, 2-fluoro-5-[5-(4-fluorophenyl)-1,2,4-oxadiazol-3-yl]- (9CI)
(CA INDEX NAME)




RN 775304-54-6 CAPLUS
CN Benzoic acid, 3-[5-(3-fluoro-4-bromo-2-fluorophenyl)-1,2,4-oxadiazol-3-yl]- (9CI)
(CA INDEX NAME)




RN 775304-55-7 CAPLUS
CN Benzoic acid, 3-[5-(3-fluoro-1,1'-biphenyl)-4-yl]-1,2,4-oxadiazol-3-yl]- (9CI)
(CA INDEX NAME)




RN 775304-48-8 CAPLUS
CN Benzoic acid, 3-[5-(3-(dimethylamino)phenyl)-1,2,4-oxadiazol-3-yl]- (9CI)
(CA INDEX NAME)




RN 775304-49-9 CAPLUS
CN Benzoic acid, 3-[5-(2,3-difluorophenyl)-1,2,4-oxadiazol-3-yl]- (9CI)
(CA INDEX NAME)




RN 775304-50-2 CAPLUS
CN Benzoic acid, 3-[5-(2-fluoro-5-methylphenyl)-1,2,4-oxadiazol-3-yl]- (9CI)
(CA INDEX NAME)




RN 775304-51-3 CAPLUS
CN Benzoic acid, 3-[5-(2-(methylthio)-3-pyridinyl)-1,2,4-oxadiazol-3-yl]- (9CI)
(CA INDEX NAME)




RN 775304-56-8 CAPLUS
CN Benzoic acid, 3-[5-(3-fluorophenyl)-1,2,4-oxadiazol-3-yl]- (9CI)
(CA INDEX NAME)




RN 775304-57-9 CAPLUS
CN Benzoic acid, 3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]- (9CI)
(CA INDEX NAME)



RN 775304-58-0 CAPLUS
CN Benzoic acid, 3-[5-(4-fluorophenyl)-1,2,4-oxadiazol-3-yl]- (9CI)
(CA INDEX NAME)




RN 775304-59-1 CAPLUS
CN Benzoic acid, 3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]-, sodium salt (9CI)
(CA INDEX NAME)




● Na


RN 775304-61-5 CAPLUS
CN Benzoic acid, 4-fluoro-3-[5-(4-fluorophenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 775304-62-6 CAPLUS
CN Benzoic acid, 5-[3-(4-fluorophenyl)-1,2,4-oxadiazol-3-yl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 775304-63-7 CAPLUS
CN Benzoic acid, 3-[5-(4-chloro-2-fluorophenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 775304-65-9 CAPLUS




RN 775304-76-2 CAPLUS
CN Benzoic acid, 3-[5-(4-azidophenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 775304-77-3 CAPLUS
CN Benzoic acid, 3-[5-(4-(phenylmethoxy)phenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




CN Benzoic acid, 3-[5-[6-(1-pyrrolidinyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 775304-66-0 CAPLUS
CN Benzoic acid, 3-[5-[6-(4-morpholinyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)



RN 775304-67-1 CAPLUS
CN Benzoic acid, 3-[5-[6-(1-piperidinyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)



RN 775304-68-2 CAPLUS
CN Benzoic acid, 3-[5-(2-fluoro-6-hydroxyphenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)





RN 775304-75-1 CAPLUS
CN Benzoic acid, 3-[5-(4-aminophenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)

ACCESSION NUMBER: 2001:833311 CAPLUS
DOCUMENT NUMBER: 135:371742
TITLE: Preparation and formulation of imidazoles as gastrin and cholecystokinin receptor ligands for treatment of gastrointestinal disorders
INVENTOR(S): Kalindjian, Sarkis Barret; Buck, Ildiko Maria; Steel, Katherine Isobel Mary; Wright, Paul Trevor; Tozer, Matthew John; Pether, Michael John; Low, Caroline Minli Rachel
PATENT ASSIGNEE(S): James Black Foundation Limited, UK
SOURCE: PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001085723	A1	20011115	WO 2001-GB1964	20010504
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BL, BY, KG, KZ, MD, RU, TJ, TM			
RM:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TG, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BU, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
GB 2379443	A1	20030312	GB 2002-25705	20010504
GB 2379443	B2	20040804		
US 2003199565	A1	20031023	US 2003-275741	20030407
PRIORITY APPL. INFO.:			GB 2000-11089	A 20000508
			WO 2001-GB1964	W 20010504

OTHER SOURCE(S): MARPAT 135:371742
GI



AB Title compds. I [wherein X and Y = independently :N, NR5, :CH, S, or O;
R5

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 = H, Me, Et, Pr, CH2Ph, OH, or CHCO2R6; R6 = H, Me, Et, Pr, or CH2Ph; R1

H (halo)hydrocarbonyl optionally interrupted by N, O, and/or S; R2 = independently H, Me, Et, Pr, or OH; R3 = independently H, Me, Et, or Pr; or R3 groups on neighboring C's may be linked to form a carbocyclic ring or double bond; or R2 and R3 on the same C may form :O; R4 = H or (halo)hydrocarbonyl optionally interrupted by N, O, and/or S; Z = a diradical derived from an (un)substituted arom. or nonarom. 5- or 6-membered carbocycle, wherein 1, 2 or 3 C's are optionally replaced by

N, O, and/or S; Q = 6-membered arom. carbocycle (un)substituted with 1 or 2

V groups and/or 1, 2, or 3 T groups, wherein 1, 2, or 3 C's are optionally replaced by N; V = CONHSO2Ph, SO2NHCOPh, CH2OH, or RTU; U = CO2H, tetrazolyl, CONHOH, or SO3H; R7 = a bond, (un)substituted hydrocarbylene, O-alkylene, SO2NRSCHR9, or CONR8CHR9; R8 and R9 = independently H, Me, or NH(CO)CH2; c = 0-1; and their pharmaceutically acceptable salts were prepd. as gastrin and/or cholecystokinin receptor ligands for treatment

of gastrointestinal disorders. For example, 5-(adamantan-1-yloxymethyl)-2-cyclohexylimidazole-1,4-dicarboxylic acid 1-tert-Bu ester (6-step prepn. given) was amidated with 3-(1-amino-2-hydroxyethyl)benzoic acid Me ester (1-step prepn. given) to give the 2-hydroxy-1-(3-methoxycarbonylphenyl)ethylcarbamoylimidazole-1-carboxylic acid tert-Bu ester (35%). Cyclization afforded the 4,5-dihydrooxazole (84%), which was reduced to the oxazole (97%), deprotected (90%), and deesterified (62%)

to give II. Eighteen invention compds. were tested in an immature rat stomach assay and showed gastrin (CCK2) antagonist activity with pKB values ranging from 5.76 to 8.72. In a guinea-pig pancreas CCK1 binding assay, the compds. exhibited pKi values ranging from 5.01 to 6.87. Compns. comprising I and a proton pump inhibitor are also described. These compns. reduce hyperplasia assocd. with administration of a proton pump inhibitor alone (no data).

IT 373648-87-4P, 3-[5-[5-(Adamantan-1-yloxymethyl)-2-cyclohexyl-1H-imidazol-4-yl]-1,2,4-oxadiazol-3-yl]benzoic acid 373648-90-9P, 3-[5-[5-(2-Adamantan-1-ylethyl)-2-cyclohexyl-1H-imidazol-4-yl]-1,2,4-oxadiazol-3-yl]benzoic acid 373648-92-1P, 3-[5-[5-(2-Adamantan-1-ylethyl)-2-o-tolyl-1H-imidazol-4-yl]-1,2,4-oxadiazol-3-yl]benzoic acid

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation and formulation of imidazoles as gastrin and cholecystokinin receptor ligands for treatment of gastrointestinal disorders).

RN 373648-87-4 CAPLUS
 CN Benzoic acid, 3-[5-[2-cyclohexyl-5-[(tricyclo[3.3.1.1.3,7]dec-1-yloxy)methyl]-1H-imidazol-4-yl]-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)


L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RL: BAC (Biological activity or effector, except adverse); BSU

(Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. and formulation of imidazoles as gastrin and cholecystokinin receptor ligands for treatment of gastrointestinal disorders)

RN 373649-40-2 CAPLUS
 CN D-Glucitol, 1-deoxy-1-(methylamino)-, 3-[5-[2-cyclohexyl-5-[(tricyclo[3.3.1.1.3,7]dec-1-yloxy)methyl]-1H-imidazol-4-yl]-1,2,4-oxadiazol-3-yl]benzoate (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 373648-87-4
 CMF C29 H34 N4 O4



CM 2

CRN 6284-40-8
 CMF C7 H17 N O5

Absolute stereochemistry.




RN 373649-41-3 CAPLUS
 CN D-Glucitol, 1-deoxy-1-(methylamino)-, 3-[5-[2-cyclohexyl-5-(2-tricyclo[3.3.1.1.3,7]dec-1-ylethyl)-1H-imidazol-4-yl]-1,2,4-oxadiazol-3-yl]benzoate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 373648-90-9
 CMF C30 H36 N4 O3


L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 373648-90-9 CAPLUS
 CN Benzoic acid, 3-[5-[2-cyclohexyl-5-(2-tricyclo[3.3.1.1.3,7]dec-1-ylethyl)-1H-imidazol-4-yl]-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 373648-92-1 CAPLUS
 CN Benzoic acid, 3-[5-[2-(2-methylphenyl)-5-(2-tricyclo[3.3.1.1.3,7]dec-1-ylethyl)-1H-imidazol-4-yl]-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)



IT 373649-40-2P 373649-41-3P 373649-42-4P


L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



CM 2

CRN 6284-40-8
 CMF C7 H17 N O5


Absolute stereochemistry.



RN 373649-42-4 CAPLUS
 CN D-Glucitol, 1-deoxy-1-(methylamino)-, 3-[5-[2-(2-methylphenyl)-5-(2-tricyclo[3.3.1.1.3,7]dec-1-ylethyl)-1H-imidazol-4-yl]-1,2,4-oxadiazol-3-yl]benzoate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 373648-92-1
 CMF C31 H32 N4 O3



CM 2
CRN 6284-40-8
CMF C7 H17 N O5

Absolute stereochemistry.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

ACCESSION NUMBER: 2000:881130 CAPLUS
DOCUMENT NUMBER: 134:42124
TITLE: Preparation of diaminothiazoles for inhibiting protein

INVENTOR(S):
kinases
Chu, Shao Song; Alegria, Larry Andrew; Bender, Steven Lee; Benedict, Suzanne Pritchett; Borchardt, Allen J.;



PATENT ASSIGNEE(S):
SOURCE: Kania, Robert Steve; Nambu, Mitchell David; Tempczyk-Russell, Anna Maria; Sarshar, Sepehr Agouron Pharmaceuticals, Inc., USA
PCT Int. Appl., 397 pp.

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000075120	A1	20001214	WO 2000-US15188	20000602
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2371158	AA	20001214	CA 2000-2371158	20000602
EP 1181283	A1	20020227	EP 2000-942660	20000602
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000011585	A	20020319	BR 2000-11585	20000602
JP 2003501420	T2	20030114	JP 2001-501601	20000602
EE 200100659	A	20030217	EE 2001-659	20000602
AU 778071	B2	20041111	AU 2000-57254	20000602
US 2002025976	A1	20020228	US 2001-783584	20010215
US 6620828	B2	20030916		
ZA 2001008291	A	20021009	ZA 2001-8291	20011009
NO 2001005045	A	20020204	NO 2001-5045	20011017
BG 106276	A	20021031	BG 2002-106276	20020103
PRIORITY APPLN. INFO.:				
				US 1999-137810P P 19990604
				US 2000-587530 B1 20000602
				WO 2000-US15188 W 20000602

OTHER SOURCE(S): MARPAT 134:42124
GI



AB The title compds. [I; R1 = H, (un)substituted alkyl, cycloalkyl, etc.; R2 = OH, halo, CN, etc.; X = C, N; Q = a divalent radical having 2 or 3 atoms selected from C, N, O, S, CR5, NR5 (wherein R5 = OH, halo, CN, etc.)

which together with C* and N* form a 5-6 membered (non)aromatic ring] which modulate and/or inhibit the activity of certain protein kinases (biol. data were given), and are useful in treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, were prepared and formulated.

E.g., a multi-step synthesis of diaminothiazole II was given. The compds. I and pharmaceutical compns. containing them are capable of mediating tyrosine kinase signal transduction in order to modulate and/or inhibit unwanted cell proliferation.

IT 312762-57-5

RL: BAC (Biological activity or effector, except adverse); BSU

(Biological study; unclassified); THU (Therapeutic use); BIOL (Biological study);


USES (Uses)

(preparation of diaminothiazoles for inhibiting protein kinases)

RN 312762-57-5 CAPLUS

CN Benzoic acid,

3-[5-[4-amino-2-[(3,4,5-trimethoxyphenyl)amino]-5-thiazolyl]-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

ACCESSION NUMBER: 1997:776160 CAPLUS

DOCUMENT NUMBER: 128:23138

TITLE: 1,2,4-oxadiazoles as adhesion-receptor antagonists

INVENTOR(S): Juraszyk, Horst; Gante, Joachim; Wurziger, Hanns; Bernotat-Danielowski, Sabine; Melzer, Guido

PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany; Juraszyk, Horst; Gante, Joachim; Wurziger, Hanns;

Bernotat-Danielowski,

SOURCE: Sabine; Melzer, Guido
PCT Int. Appl., 49 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9744333	A1	19971127	WO 1997-EP2555	19970520
W: AU, BR, CA, CN, CZ, HU, JP, KR, MX, NO, PL, RU, SK, UA, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,				
SE				
DE 19620041	A1	19980129	DE 1996-19620041	19960517
ZA 9704234	A	19971211	ZA 1997-4234	19970515
AU 9729579	A1	19971209	AU 1997-29579	19970520
PRIORITY APPLN. INFO.:			DE 1996-19620041	A 19960517
			WO 1997-EP2555	W 19970520

OTHER SOURCE(S): MARPAT 128:23138

AB Oxadiazoles R1U(CH2)m(CH)n'(NHR2')-1,2,4-oxadiazol-3,5-diyl-
C6H4V(CH)q(Ar)(CH2)p(CH)n(NHR2)WR3 [R1 = (un)substituted amino, amidino,
guanidino, Ph, pyrimidinyl, tetrahydropyrimidinyl, pyridyl,
tetrahydropyridyl, piperazinyl, or piperidinyl; R2, R2' = H, alkanoyl,
carbalkoxy, alkylsulfonyl or (un)substituted benzoyl, heteroaroyl, or
phenylsulfonyl; R3 = OH, alkoxy, carbalkoxyamino, alkoxycarbonylamino,
or an amino acid residue; U = bond or O; V = bond, O, CONH, S, SO, SO2; W
= CO or SO2 (for V = bond and n, p, q = 0); Ar = (un)substituted phenyl;

m = 0-4; n, n', q = 0, 1; p = 0-2) or their salts were prepared as
adhesion-receptor antagonists. Thus, 5-(p-amidinophenyl)-3-[3-
(carboxyethylaminocarbonyl)phenyl]-1,2,4-oxadiazole hydrochloride was
prepared from 3-cyanobenzoic acid, 4-cyanobenzoyl chloride, and
β-alanine tert-Bu ester hydrochloride.


199447-11-5P

IT RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(oxadiazoles as adhesion-receptor antagonists)

RN 199447-11-5 CAPLUS

CN Benzoic acid, 3-[5-(4-cyanophenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA

INDEX
NAME)

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

20.21

181.75

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-2.92

-2.92

STN INTERNATIONAL LOGOFF AT 10:53:08 ON 19 JAN 2005